These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1785186)

  • 1. [A comparison of the protective properties of preparations of the virion and nonvirion ("soluble") antigens of the tick-borne encephalitis virus].
    Liapustin VN; Pivanova GP; Karavanov AS; Lashkevich VA
    Vopr Virusol; 1991; 36(6):498-500. PubMed ID: 1785186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Isolation of split and whole-virion tick-borne encephalitis vaccines in an experiment and the characteristics of their immunogenic and antigenic properties].
    Osipova EG; Solianik RG; Fedorov IuV; Tymchishin PN
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Aug; (8):50-3. PubMed ID: 3687295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tick-borne encephalitis DNA vaccines in monkeys.
    Schmaljohn C; Custer D; VanderZanden L; Spik K; Rossi C; Bray M
    Virology; 1999 Oct; 263(1):166-74. PubMed ID: 10544091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The protective activity of preparations made from the tick-borne encephalitis virus grown using different cell cultures].
    El'bert LB; Vorovich MF; Terletskaia EN; Lisitsina EA; Atanadze SN; Sidorovich IG; Khozinskiĭ VV; Tugizov ShM; Kushch AA; Khapchaev IuKh
    Zh Mikrobiol Epidemiol Immunobiol; 1992 Jan; (1):25-8. PubMed ID: 1414102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis.
    Heinz FX; Allison SL; Stiasny K; Schalich J; Holzmann H; Mandl CW; Kunz C
    Vaccine; 1995 Dec; 13(17):1636-42. PubMed ID: 8719513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new prospective vaccine against tick-borne encephalitis].
    Chumakov MP; Rubin SG; Semashko IV; Karavanov AS; Avdeeva LI; Gagarina AV; Gambarian AS; Matrosovich MN; Mart'ianova LI; Mironova LL
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jan; (1):36-40. PubMed ID: 1858468
    [No Abstract]   [Full Text] [Related]  

  • 7. [A comparison of the immune response induced by DNA or by an inactivated vaccine against tick-borne encephalitis].
    Morozova OV; Popova RV; Maksimova TG; Mitrofanova EE; Bakhvalova VN
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (2):54-7. PubMed ID: 10808575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The relationship of the antigenic characteristics of the tick-borne encephalitis virus to the level of the protective activity of inactivated cultured vaccines].
    Vorob'eva MS; Rasshchepkina MN
    Zh Mikrobiol Epidemiol Immunobiol; 1992; (11-12):35-7. PubMed ID: 1301660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Isolation of virion and low-molecular nonvirion ("soluble") antigens of the tick-borne encephalitis virus by fractional precipitation with polyethylene glycol].
    Liapustin VN; Lashkevich VA
    Vopr Virusol; 1983; 28(4):122-4. PubMed ID: 6636699
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of direct solid-phase immunoenzyme analysis for assessing the immunological activity of a vaccine against tick-borne encephalitis].
    Timofeev AV; El'bert LB; Terletskaia EN; Mal'dov DG; Karavanov AS
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Sep; (9):89-93. PubMed ID: 3318250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nonvirion (soluble) antigen of the tick-borne encephalitis virus].
    Gritsun TS; Liapustin VN; Karganova GG; Lashkevich VA
    Vopr Virusol; 1988; 33(2):217-27. PubMed ID: 3414069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of inbred mice for assessing the neurovirulence of strains of the tick-borne encephalitis virus complex and the immunogenicity of a concentrated tick-borne encephalitis vaccine].
    Kan GA; Borsuk EA; Vorob'eva MS
    Vopr Virusol; 1982; 27(4):461-4. PubMed ID: 7135927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The purification of tick-borne encephalitis virus preparations of cellular DNA].
    El'bert LB; Terletskaia EN; Timofeev AV; Amosenko FA; Khapchaev IuKh; Mironova LL; Svitkin IuV; Vorovich MF; Lisitsyna EA
    Vopr Virusol; 1990; 35(3):219-21. PubMed ID: 2219855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the "Immuno" firm].
    Vorob'eva MS; Rasshchepkina MN; Ladyzhenskaia IP; Gorbunov MA; Pavlova LI; Bektimirov TA
    Vopr Virusol; 1996; 41(5):221-4. PubMed ID: 8967069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in the synthesis of the virion antigen of the tick-borne encephalitis virus after passage through ixodid ticks and small mammals].
    Liapustin VN; Chunikhin SP; Reshetnikov IA; Lashkevich VA
    Vopr Virusol; 1987; 32(4):451-6. PubMed ID: 3318134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dependence of the synthesis of virion structures in the tick-borne encephalitis virus on the cell culture type].
    Liapustin VN; Lashkevich VA; Mustafina AN; Reshetnikov IA; Chunikhin SP
    Vopr Virusol; 1987; 32(6):701-9. PubMed ID: 3445588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of a low-molecular nonvirion ("soluble") antigen from the tick-borne encephalitis virus].
    Liapustin VN; Zhankov AI; Dzhivanian TI; Lashkevich VA
    Vopr Virusol; 1983; (2):200-7. PubMed ID: 6868559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nonstructural protein NV5 of the tick-borne encephalitis virus possesses precipitating activity characteristic for the nonvirion (soluble) antigen].
    Liapustin VN; Gritsun TS; Lashkevich VA
    Vopr Virusol; 1986; 31(3):329-33. PubMed ID: 2945323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concentrated purified vaccine against tick-borne encephalitis. An immunological evaluation in experiments on mice].
    Khotlubeĭ LI; Pervikov IuV; Krutianskaia GL; Vil'ner LM; Semenov BF
    Vopr Virusol; 1982; 27(3):316-20. PubMed ID: 7123913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine.
    Fleeton MN; Liljeström P; Sheahan BJ; Atkins GJ
    J Gen Virol; 2000 Mar; 81(Pt 3):749-58. PubMed ID: 10675413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.